Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer.
about
The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic reviewStrategies for postmarketing surveillance of drugs and devices in patients with ESRD undergoing dialysisExploring Big Data in Hematological Malignancies: Challenges and Opportunities.Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: results of a Phase II trial.Eligibility for bevacizumab as an independent prognostic factor for patients with advanced non-squamous non-small cell lung cancer: a retrospective cohort study.Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014.Patterns of care, predictors, and outcomes of chemotherapy in elderly women with early-stage uterine carcinosarcoma: a population-based analysis.Disparate survival trends in histologic subtypes of metastatic non-small cell lung cancer: a population-based analysisUse of Bevacizumab in Community Settings: Toxicity Profile and Risk of Hospitalization in Patients With Advanced Non-Small-Cell Lung CancerA Novel, Potent, Small Molecule AKT Inhibitor Exhibits Efficacy against Lung Cancer Cells In VitroPatterns and predictors of first-line chemotherapy use among adults with advanced non-small cell lung cancer in the cancer research network.U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy.New targetable oncogenes in non-small-cell lung cancer.Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer: a SEER-Medicare analysis.Prognostic factors for long term survival in patients with advanced non-small cell lung cancer.Prescription of extended-duration thromboprophylaxis after high-risk, abdominopelvic cancer surgery.A potential new enriching trial design for selecting non-small-cell lung cancer patients with no predictive biomarker for trials based on both histology and early tumor response: further analysis of a thalidomide trialSafety, Effectiveness, and Costs of Bevacizumab-Based Therapy in Southern Spain: A Real World Experience.Customised, Individualised Treatment of Metastatic Non-Small-Cell Lung Carcinoma (NSCLC)Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?The use of clinical trials in comparative effectiveness research on mental health.Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak TrialsFirst-Line Treatment with Bevacizumab and Platinum Doublet Combination in Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study in US Oncology Community Practices.Comparative effectiveness of adjunctive bevacizumab for advanced lung cancer: the cancer research network experienceAnti-vascular endothelial growth factor therapy in the era of personalized medicine.Bevacizumab in advanced NSCLC: chemotherapy partners and duration of use.A review of the management of elderly patients with non-small-cell lung cancer.Pharmacotherapy for treatment of lung cancer in the elderly.A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancer.Treatment patterns and cost-effectiveness of first line treatment of advanced non-squamous non-small cell lung cancer in Medicare patients.Prolongation of life by adoptive cell therapy with cascade primed immune cells in four patients with non-small cell lung cancer stages IIIB and IV and a pancoast tumor: a case series.Advanced lung cancer in the older patient: is there a role for bevacizumab?Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.Comparative effectiveness of radiotherapy with vs. without temozolomide in older patients with glioblastoma.Association between p53 codon 72 genetic polymorphisms and tobacco use and lung cancer risk in a Chinese population.Effect of Angiotensin System Inhibitors on Survival in Patients Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer.Darkness before dawn, but will the sun always rise?Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology.Prognostic Impact of Palliative Primary Tumor Resection for Unresectable Stage 4 Colorectal Cancer: Using a Propensity Score Analysis.Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
P2860
Q26824086-4DB0C727-4D04-4D62-9CAF-85649F5178C9Q27694667-E1F32906-5D12-4B45-81B7-4C1725E30AA9Q31095966-01CB50E2-B557-4044-BCBE-AFEA4DBC483AQ33408323-2A0C8979-53C5-49F0-999F-B9635EB4B70AQ34651916-49899F9B-0454-4A97-8A51-76C3E106F06BQ35813168-A351196E-C683-406D-AB98-8D01DB4CC104Q35849504-A9186DF3-F77A-4619-87E0-DAA57467C354Q35993134-857108A2-8947-4103-906F-4558092514DAQ36073707-D2542283-5089-4959-98A0-683E59CC8495Q36187059-52416AF7-EB4C-4589-AD8A-2584C4FA7C5DQ36374254-844EF166-1E53-4F35-821A-5269AC9E7E73Q36478734-D5AA8F23-08C7-4579-8AC7-6AD5D4C870A4Q36660677-09D053D1-6F19-4A09-B1AB-C4B074AAC3A3Q36871717-D9152D80-6B1F-4CEF-8B74-5B72C28E3965Q36924926-7B86C1D7-E24B-4B2B-99F1-F11ADC55F1BCQ36927644-B03A333A-FFB3-4A60-8B3F-7C9D7750AC8DQ36977437-39BDF886-4955-4958-8DC8-D05BE346E362Q36993476-A6C5B104-51EA-4AD7-AEEF-40EF740DB42EQ36996220-5BA76DFF-6251-496A-A840-4EDE525ECFEEQ36999705-7B700A09-93B9-46D4-829A-A146540EC989Q37019471-CEF93270-A38C-401A-8B01-87942446BCD6Q37242517-632B3ECA-6FB5-4498-BFD9-356CB92576BDQ37297943-F0389D2D-3231-45B7-9B68-E0C93C531C72Q37372172-995B79A3-F310-4CCE-B147-07B44A31CC2FQ38086799-0A4F5C78-43AD-4AC9-8991-14FD36C426BEQ38132693-42136EBF-50F7-4939-8721-81C0367DEA8EQ38233740-8749D381-4110-48EE-B6C1-1564D3834B5EQ38386745-D6E3EAB7-F721-4554-B34D-00414A0B3013Q40155605-199007FB-46B3-4D64-990A-9979C0716B5CQ40602351-4B9C3DA8-572C-4DA9-AF7E-1F15D544B992Q41847059-3A124334-1D1C-4912-A71F-75CD41B853E4Q42355190-E3650627-59FC-47A3-A4A8-E83CB627B9C7Q45126932-DA4AAD48-0B3A-4EAB-B0B9-6BCE25905E60Q45298561-90030FF4-A4CA-49A8-AD59-05F90E508735Q45893620-388045DB-0993-4EBD-9705-FB8830A2DE03Q46018831-E2B12C5F-75C1-45EF-A497-3350D3819B35Q46935443-0215CCEA-3C5D-4315-8D39-CF48DE01075CQ53061916-386ED053-CE31-4EE5-93AF-4E9DF4634465Q53087607-4E85835E-3EBD-49FA-8004-9E89FDA708E8Q53608931-80E93C19-A96D-47F1-B931-8B24B37C2986
P2860
Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Carboplatin and paclitaxel wit ...... ed non-small cell lung cancer.
@ast
Carboplatin and paclitaxel wit ...... ed non-small cell lung cancer.
@en
type
label
Carboplatin and paclitaxel wit ...... ed non-small cell lung cancer.
@ast
Carboplatin and paclitaxel wit ...... ed non-small cell lung cancer.
@en
prefLabel
Carboplatin and paclitaxel wit ...... ed non-small cell lung cancer.
@ast
Carboplatin and paclitaxel wit ...... ed non-small cell lung cancer.
@en
P2093
P2860
P356
P1476
Carboplatin and paclitaxel wit ...... ed non-small cell lung cancer.
@en
P2093
Aileen B Chen
Deborah Schrag
Dhruv B Sharma
Jane C Weeks
Stacy W Gray
P2860
P304
P356
10.1001/JAMA.2012.454
P407
P577
2012-04-01T00:00:00Z